Predictive biology expansion pixlbio is expanding from iPSC-derived liver models to cardiac and renal models, presenting new cross-sell opportunities for pharma and biotech clients seeking comprehensive organ system coverage in predictive safety and efficacy testing.

High-value collaborations Trusted by 11 of the top 20 pharma companies and leading biotechs, pixlbio already has a strong reference base that can be leveraged to win new partnerships through joint development, custom models, and expanded SaaS access.

AI‑driven phenomics The platform combines AI-powered phenomics with high-throughput imaging to generate rich, scalable data, enabling upsell of data analytics, dashboards, and cloud-based SaaS tiers to accelerate drug discovery and safety profiling.

Proprietary models Recent pixHep launch adds a scalable hepatocyte model to the portfolio, signaling appetite for additional disease and organ-specific models that can be packaged as modular offerings or sold as service-based studies.

Global access and quality ISO 9001:2015 certification and multinational merger history position pixlbio as a reliable supplier for global pharma and research institutions, suggesting opportunities in large-volume projects, CRO partnerships, and long-term contracting.